Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model

Wenbo Zhang, Harumasa Yokota, Zhimin Xu, Subhadra P. Narayanan, Lauren Yancey, Akitoshi Yoshida, Dennis M. Marcus, Robert William Caldwell, Ruth B Caldwell, Steven E. Brooks

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose. To investigate the therapeutic use and mechanisms of action of normobaric hyperoxia to promote revascularization and to prevent neovascularization in a mouse model of oxygen-induced ischemic retinopathy. Methods. Hyperoxia treatment (HT, 40%-75% oxygen) was initiated on postnatal day (P) 14 during the pre-proliferative phase of ischemic retinopathy. Immunohistochemistry, ELISA, and quantitative PCR were used to assess effects on retinal vascular repair and pathologic angiogenesis in relation to glial cell injury, VEGF protein, and mRNA levels of key mediators of pathologic angiogenesis. Effects of intravitreal injections of VEGF and the VEGF inhibitor VEGFR1/Fc fusion protein were also studied. Results. Administration of HT during the ischemic pre-proliferative phase of retinopathy effectively accelerated the process of revascularization while preventing the development of vitreous neovascularization. HT enhanced the formation of specialized endothelial tip cells at the edges of the repairing capillary networks and blocked the overexpression of several molecular mediators of angiogenesis, inflammation, and extracellular proteolysis. HT markedly reduced the reactive expression of GFAP in Müller cells and improved the morphology of astrocytes in the avascular region of the retina. Exogenous VEGF administered into the vitreous on P14 was not sufficient to cause vitreous neovascularization in the HT mice. Injection of the VEGF antagonist VEGFR1/Fc blocked both pathologic and physiological angiogenesis and did not rescue astrocytes. Conclusions. HT may be clinically useful to facilitate vascular repair while blocking neovascularization in the pre-proliferative stage of ischemic retinopathy by correcting a broad range of biochemical and cellular abnormalities.

Original languageEnglish (US)
Pages (from-to)6384-6395
Number of pages12
JournalInvestigative Ophthalmology and Visual Science
Volume52
Issue number9
DOIs
StatePublished - Aug 1 2011

Fingerprint

Hyperoxia
Vascular Endothelial Growth Factor A
Pathologic Neovascularization
Astrocytes
Physiologic Neovascularization
Oxygen
Therapeutics
Inflammation Mediators
Retinal Vessels
Intravitreal Injections
Therapeutic Uses
Neuroglia
Proteolysis
Blood Vessels
Retina
Proteins
Endothelial Cells
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Zhang, W., Yokota, H., Xu, Z., Narayanan, S. P., Yancey, L., Yoshida, A., ... Brooks, S. E. (2011). Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model. Investigative Ophthalmology and Visual Science, 52(9), 6384-6395. https://doi.org/10.1167/iovs.11-7666

Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model. / Zhang, Wenbo; Yokota, Harumasa; Xu, Zhimin; Narayanan, Subhadra P.; Yancey, Lauren; Yoshida, Akitoshi; Marcus, Dennis M.; Caldwell, Robert William; Caldwell, Ruth B; Brooks, Steven E.

In: Investigative Ophthalmology and Visual Science, Vol. 52, No. 9, 01.08.2011, p. 6384-6395.

Research output: Contribution to journalArticle

Zhang, W, Yokota, H, Xu, Z, Narayanan, SP, Yancey, L, Yoshida, A, Marcus, DM, Caldwell, RW, Caldwell, RB & Brooks, SE 2011, 'Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model', Investigative Ophthalmology and Visual Science, vol. 52, no. 9, pp. 6384-6395. https://doi.org/10.1167/iovs.11-7666
Zhang, Wenbo ; Yokota, Harumasa ; Xu, Zhimin ; Narayanan, Subhadra P. ; Yancey, Lauren ; Yoshida, Akitoshi ; Marcus, Dennis M. ; Caldwell, Robert William ; Caldwell, Ruth B ; Brooks, Steven E. / Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model. In: Investigative Ophthalmology and Visual Science. 2011 ; Vol. 52, No. 9. pp. 6384-6395.
@article{591e13468e484dafad1d6412c181e5a9,
title = "Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model",
abstract = "Purpose. To investigate the therapeutic use and mechanisms of action of normobaric hyperoxia to promote revascularization and to prevent neovascularization in a mouse model of oxygen-induced ischemic retinopathy. Methods. Hyperoxia treatment (HT, 40{\%}-75{\%} oxygen) was initiated on postnatal day (P) 14 during the pre-proliferative phase of ischemic retinopathy. Immunohistochemistry, ELISA, and quantitative PCR were used to assess effects on retinal vascular repair and pathologic angiogenesis in relation to glial cell injury, VEGF protein, and mRNA levels of key mediators of pathologic angiogenesis. Effects of intravitreal injections of VEGF and the VEGF inhibitor VEGFR1/Fc fusion protein were also studied. Results. Administration of HT during the ischemic pre-proliferative phase of retinopathy effectively accelerated the process of revascularization while preventing the development of vitreous neovascularization. HT enhanced the formation of specialized endothelial tip cells at the edges of the repairing capillary networks and blocked the overexpression of several molecular mediators of angiogenesis, inflammation, and extracellular proteolysis. HT markedly reduced the reactive expression of GFAP in M{\"u}ller cells and improved the morphology of astrocytes in the avascular region of the retina. Exogenous VEGF administered into the vitreous on P14 was not sufficient to cause vitreous neovascularization in the HT mice. Injection of the VEGF antagonist VEGFR1/Fc blocked both pathologic and physiological angiogenesis and did not rescue astrocytes. Conclusions. HT may be clinically useful to facilitate vascular repair while blocking neovascularization in the pre-proliferative stage of ischemic retinopathy by correcting a broad range of biochemical and cellular abnormalities.",
author = "Wenbo Zhang and Harumasa Yokota and Zhimin Xu and Narayanan, {Subhadra P.} and Lauren Yancey and Akitoshi Yoshida and Marcus, {Dennis M.} and Caldwell, {Robert William} and Caldwell, {Ruth B} and Brooks, {Steven E.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1167/iovs.11-7666",
language = "English (US)",
volume = "52",
pages = "6384--6395",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "9",

}

TY - JOUR

T1 - Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model

AU - Zhang, Wenbo

AU - Yokota, Harumasa

AU - Xu, Zhimin

AU - Narayanan, Subhadra P.

AU - Yancey, Lauren

AU - Yoshida, Akitoshi

AU - Marcus, Dennis M.

AU - Caldwell, Robert William

AU - Caldwell, Ruth B

AU - Brooks, Steven E.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Purpose. To investigate the therapeutic use and mechanisms of action of normobaric hyperoxia to promote revascularization and to prevent neovascularization in a mouse model of oxygen-induced ischemic retinopathy. Methods. Hyperoxia treatment (HT, 40%-75% oxygen) was initiated on postnatal day (P) 14 during the pre-proliferative phase of ischemic retinopathy. Immunohistochemistry, ELISA, and quantitative PCR were used to assess effects on retinal vascular repair and pathologic angiogenesis in relation to glial cell injury, VEGF protein, and mRNA levels of key mediators of pathologic angiogenesis. Effects of intravitreal injections of VEGF and the VEGF inhibitor VEGFR1/Fc fusion protein were also studied. Results. Administration of HT during the ischemic pre-proliferative phase of retinopathy effectively accelerated the process of revascularization while preventing the development of vitreous neovascularization. HT enhanced the formation of specialized endothelial tip cells at the edges of the repairing capillary networks and blocked the overexpression of several molecular mediators of angiogenesis, inflammation, and extracellular proteolysis. HT markedly reduced the reactive expression of GFAP in Müller cells and improved the morphology of astrocytes in the avascular region of the retina. Exogenous VEGF administered into the vitreous on P14 was not sufficient to cause vitreous neovascularization in the HT mice. Injection of the VEGF antagonist VEGFR1/Fc blocked both pathologic and physiological angiogenesis and did not rescue astrocytes. Conclusions. HT may be clinically useful to facilitate vascular repair while blocking neovascularization in the pre-proliferative stage of ischemic retinopathy by correcting a broad range of biochemical and cellular abnormalities.

AB - Purpose. To investigate the therapeutic use and mechanisms of action of normobaric hyperoxia to promote revascularization and to prevent neovascularization in a mouse model of oxygen-induced ischemic retinopathy. Methods. Hyperoxia treatment (HT, 40%-75% oxygen) was initiated on postnatal day (P) 14 during the pre-proliferative phase of ischemic retinopathy. Immunohistochemistry, ELISA, and quantitative PCR were used to assess effects on retinal vascular repair and pathologic angiogenesis in relation to glial cell injury, VEGF protein, and mRNA levels of key mediators of pathologic angiogenesis. Effects of intravitreal injections of VEGF and the VEGF inhibitor VEGFR1/Fc fusion protein were also studied. Results. Administration of HT during the ischemic pre-proliferative phase of retinopathy effectively accelerated the process of revascularization while preventing the development of vitreous neovascularization. HT enhanced the formation of specialized endothelial tip cells at the edges of the repairing capillary networks and blocked the overexpression of several molecular mediators of angiogenesis, inflammation, and extracellular proteolysis. HT markedly reduced the reactive expression of GFAP in Müller cells and improved the morphology of astrocytes in the avascular region of the retina. Exogenous VEGF administered into the vitreous on P14 was not sufficient to cause vitreous neovascularization in the HT mice. Injection of the VEGF antagonist VEGFR1/Fc blocked both pathologic and physiological angiogenesis and did not rescue astrocytes. Conclusions. HT may be clinically useful to facilitate vascular repair while blocking neovascularization in the pre-proliferative stage of ischemic retinopathy by correcting a broad range of biochemical and cellular abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=80053479183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053479183&partnerID=8YFLogxK

U2 - 10.1167/iovs.11-7666

DO - 10.1167/iovs.11-7666

M3 - Article

VL - 52

SP - 6384

EP - 6395

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 9

ER -